Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.52 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.52 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.44 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.44 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.44 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.44 |
| ▸ | RORA | P35398 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20072035 | 1.00 | PDK1 (0.52) | PDK1PDK2PDK3PDK4KCNJ11 | |
| SCHEMBL20072110 | 0.85 | PDK1 (0.49) | PDK1PDK2PDK3PDK4KCNJ11 | |
| SCHEMBL20068672 | 0.85 | PDK1 (0.49) | PDK1PDK2PDK3PDK4KCNJ11 | |
| SCHEMBL20072038 | 0.85 | CACNA1B (0.46) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL18921671 | 0.84 | PDK1 (0.49) | PDK1PDK2PDK3PDK4KCNJ11 | |
| SCHEMBL30451083 | 0.84 | PDK1 (0.49) | PDK1PDK2PDK3PDK4KCNJ11 | |
| SCHEMBL18921672 | 0.84 | PDK1 (0.49) | PDK1PDK2PDK3PDK4KCNJ11 | |
| SCHEMBL20060896 | 0.83 | PDK1 (0.47) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL20068678 | 0.83 | PDK1 (0.47) | PDK1PDK2PDK3PDK4MEN1 | |
| SCHEMBL20072129 | 0.82 | PARP1 (0.49) | PDK1PDK2PDK3PDK4KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526203-B1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | US | disclosed |
| WO-2018071313-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | PDK1 2640/4885PDK2 2328/4885PDK3 2357/4885 |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | PDK1 2640/4885PDK2 2328/4885PDK3 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.